ABERNETHY MATT
SEC CIK 1724097 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | CFO | 42.8K | — | $11.83M | 29 | 2021-12-01 | 2026-09-14 |
Most active insiders at NBIX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | GORMAN KEVIN CHARLES | Dir | — | $37.82M |
| 2 | Cooke Julie | CHRO | — | $5.77M |
| 3 | Gano Kyle | CEO, Dir | — | $4.87M |
| 4 | Lippoldt Darin | CLO | — | $4.20M |
| 5 | SHERWIN STEPHEN A | Dir | — | $4.13M |
| 6 | Delaet Ingrid | Chief Regulatory Off | — | $3.75M |
| 7 | Onyia Jude | CSO | — | $3.47M |
| 8 | RASTETTER WILLIAM H | Dir | — | $2.73M |
| 9 | POPS RICHARD F | Dir | — | $2.36M |
| 10 | LYONS GARY A | Dir | — | $2.29M |
| 15 | ABERNETHY MATT | CFO | — | $363.3K |
Transactions 29
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-15 17:02 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | A - Grant | $0.00 | +5,020 | 47.8K | +12% | $0 |
| T | 2026-09-15 17:02 | 2026-09-11 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | F - Tax | $156.22 | -2,709 | 45.1K | -6% | -$423.2K |
| T | 2026-09-15 17:02 | 2026-09-14 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $157.20 | -2,311 | 42.8K | -5% | -$363.3K |
| 2026-03-05 | 2026-03-04 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | G - Gift | $0.00 | -2,249 | 42.8K | -5% | $0 | |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $0.00 | +6,940 | 40.3K | +21% | $0 |
| DM | 2026-02-17 | 2026-02-12+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | F - Tax | $123.99 | -9,124 | 38.1K | -19% | -$1.13M |
| D | 2026-02-17 | 2026-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | A - Grant | $0.00 | +9,968 | 50.3K | +25% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | F - Tax | $136.06 | -1,368 | 37.1K | -4% | -$186.1K |
| D | 2026-02-03 | 2026-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $0.00 | +2,437 | 38.5K | +7% | $0 |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $0.00 | +4,807 | 37.0K | +15% | $0 |
| DM | 2025-02-14 | 2025-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale+OE | $116.86 | -2,558 | 35.8K | -7% | -$298.9K |
| D | 2025-02-12 | 2025-02-08 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $0.00 | +1,860 | 34.5K | +6% | $0 |
| D | 2025-02-12 | 2025-02-10 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale+OE | $118.27 | -980 | 33.6K | -3% | -$115.9K |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $0.00 | +2,436 | 34.0K | +8% | $0 |
| D | 2025-02-04 | 2025-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale+OE | $152.87 | -1,283 | 32.7K | -4% | -$196.1K |
| D | 2024-08-15 | 2024-08-13 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $73.60 | +14.1K | 45.6K | +45% | +$1.04M |
| D | 2024-08-15 | 2024-08-13 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale+OE | $150.38 | -14.1K | 31.5K | -31% | -$2.12M |
| D | 2024-07-18 | 2024-07-16 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale+OE | $150.04 | -900 | 31.5K | -3% | -$135.0K |
| D | 2024-07-18 | 2024-07-16 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $73.60 | +900 | 32.4K | +3% | +$66.2K |
| DM | 2024-05-16 | 2024-05-14+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale+OE | $137.95 | -30.0K | 31.5K | -49% | -$4.14M |
| DM | 2024-05-16 | 2024-05-14+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | M - OptEx | $73.60 | +30.0K | 46.5K | +182% | +$2.21M |
| D | 2024-02-15 | 2024-02-13 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $132.85 | -1,352 | 31.5K | -4% | -$179.6K |
| M | 2024-02-08 | 2024-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $138.73 | -2,260 | 30.3K | -7% | -$313.5K |
| 2024-02-02 | 2024-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $140.72 | -1,283 | 28.3K | -4% | -$180.5K | |
| 2023-08-23 | 2023-08-21 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $107.39 | -2,132 | 27.1K | -7% | -$229.0K | |
| M | 2023-02-08 | 2023-02-06+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $102.61 | -28.6K | 35.8K | -44% | -$2.93M |
| 2023-02-02 | 2023-01-31 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $109.98 | -1,283 | 21.4K | -6% | -$141.1K | |
| M | 2022-02-09 | 2022-02-07+ | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $80.53 | -4,290 | 19.3K | -18% | -$345.5K |
| 2021-12-03 | 2021-12-01 | NBIX | NEUROCRINE BIOSCIENCES INC | ABERNETHY MATT | CFO | S - Sale | $82.59 | -1,645 | 16.3K | -9% | -$135.9K |
Purchase Sale Sale after option exercise All abbreviations